Table 1 Demographic, clinical, laboratory features and used treatments of patients with systemic lupus erythematosus (n = 84)
Demographic features | Value |
 Male/female, n | 6/78 |
 Mean age ± SD (years) | 41.3 ± 12.2 |
 Mean disease duration ± SD (months) | 142.1 ± 103.8 |
Clinical manifestations, n (%) | |
 Joint involvement | 57 (67.8) |
 Skin involvement | 58 (69.0) |
 Serositis | 18 (21.4) |
 Hematological manifestations | 37 (44.0) |
 Neuropsychiatric involvement | 10 (11.9) |
 Renal involvement | 31 (36.9) |
Laboratory manifestations, n (%) | |
 Antinuclear antibodies | 84 (100.0) |
 Anti-DNA | 69 (82.1) |
 Anti-Sm | 13 (15.5) |
 Anti-SSA | 24 (28.6) |
 Anti-SSB | 10 (11.9) |
 Anti-RNP | 10 (11.9) |
 Anti-cardiolipin IgG/IgM | 30 (35.7) |
 Anti-β2Glicoprotein I IgG/IgM | 8 (9.5) |
 Lupus anticoagulant | 12 (14.3) |
 Low C3 levels | 32 (38.1) |
 Low C4 levels | 44 (52.4) |
Treatments, n (%) | |
 Corticosteroids | 60 (71.4) |
 Hydroxychloroquine | 54 (64.3) |
 Cyclosporine A | 19 (22.6) |
 Methotrexate | 17 (20.2) |
 Cyclophosphamide | 19 (22.6) |
 Mycophenolate mofetil | 15 (17.8) |
 Azathioprine | 18 (21.4) |
 ASA | 25 (29.7) |
 Anticoagulant therapy | 9 (10.7) |